मूलभूत आँकड़े
| LEI | 529900Q55QAG41CCAC11 |
| CIK | 1104506 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Insmed Incorporated
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| August 12, 2025 |
Exhibit 99.1 FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease — Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10 mg and 25 mg Doses Approved for the Treatment of NCFB — — BRINSUPRI |
|
| August 12, 2025 |
Exhibit 99.2 August 12, 2025 FDA Approval of BRINSUPRI™ for Patients with Non-Cystic Fibrosis Bronchiectasis FDA: Food & Drug Administration Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements th |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INCO |
|
| August 7, 2025 |
Exhibit 99.1 Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $107.4 Million for the Second Quarter of 2025, Reflecting 19% Growth Over the Second Quarter of 2024— —NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, 2025— —TPIP Prog |
|
| August 7, 2025 |
Exhibit 99.2 August 7, 2025 Second-Quarter 2025 Earnings Presentation Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertain |
|
| August 7, 2025 |
Exhibit 10.1 April 16, 2025 Drayton Wise [***] Dear Drayton: This letter, upon signature by the parties, will constitute our agreement (“Agreement”) effective April 17, 2025 (the “Effective Date”) concerning the services of J. Drayton Wise (“Consultant”) as a consultant to Insmed Incorporated (“Company”). 1.Services. Consultant will provide consulting services to Company, as may be requested by th |
|
| June 13, 2025 |
Insmed Announces Proposed $650 Million Public Offering of Common Stock Exhibit 99.1 Insmed Announces Proposed $650 Million Public Offering of Common Stock BRIDGEWATER, N.J., June 11, 2025 /PRNewswire/ - Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it intends to offer and sell $650 million of sha |
|
| June 13, 2025 |
INSMED INCORPORATED Common Stock, Par Value $0.01 Per Share Underwriting Agreement Exhibit 1.1 EXECUTION VERSION INSMED INCORPORATED Common Stock, Par Value $0.01 Per Share Underwriting Agreement June 11, 2025 Goldman Sachs & Co. LLC Leerink Partners LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC 200 West Street, New York, New York 10282 c/o Leerink Partners LLC 53 State Street, 40th Floor Boston |
|
| June 13, 2025 |
Insmed Announces Pricing of $750 Million Public Offering of Common Stock Exhibit 99.2 Insmed Announces Pricing of $750 Million Public Offering of Common Stock BRIDGEWATER, N.J., June 11, 2025 /PRNewswire/ - Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it priced an underwritten public offering of 7 |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction (Commission (IRS Employer of incorp |
|
| June 12, 2025 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Number 333-272088 PROSPECTUS SUPPLEMENT (To Prospectus dated May 19, 2023) 7,812,500 Shares Common Stock We are offering 7,812,500 shares of our common stock. |
|
| June 12, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE 424(b)(5) (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Fees to be Paid Equity Common Stock, par value $0. |
|
| June 11, 2025 |
SUBJECT TO COMPLETION, DATED JUNE 11, 2025 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File |
|
| June 10, 2025 |
Exhibit 99.2 June 10, 2025 Topline Results of Phase 2b Study of TPIP in PAH Patients TPIP: Treprostinil Palmitil Inhalation Powder | PAH: pulmonary arterial hypertension Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform A |
|
| June 10, 2025 |
Exhibit 99.1 Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension –The Study Met Primary and All Secondary Efficacy Endpoints– ▫ Statistically Significant 35% Placebo-Adjusted Reduction from Baseline in Pulmonary Vascular Resistance for the Primary Endpoint (p<0.001) ▫ |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 16, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities (1) Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (2)(3) Equity Common Stock, par value $0. |
|
| May 16, 2025 |
As filed with the Securities and Exchange Commission on May 16, 2025 As filed with the Securities and Exchange Commission on May 16, 2025 Registration No. |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 8, 2025 |
INSMED INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE 2025 INDUCEMENT PLAN FOR U. |
|
| May 8, 2025 |
INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE 2025 INDUCEMENT PLAN FOR U. |
|
| May 8, 2025 |
INSMED INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE 2025 INDUCEMENT PLAN FOR NON-U. |
|
| May 8, 2025 |
Exhibit 99.1 Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Over the First Quarter of 2024— —NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, 2025— —Phase 2b Stud |
|
| May 8, 2025 |
Exhibit 99.2 May 8, 2025 First-Quarter 2025 Earnings Presentation Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INC |
|
| May 8, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 8, 2025 |
INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE 2025 INDUCEMENT PLAN FOR NON-U. |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File |
|
| April 24, 2025 |
Exhibit 99.1 Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028 BRIDGEWATER, N.J., April 24, 2025/PRNewswire/ - Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it h |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Def |
|
| April 4, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission F |
|
| February 24, 2025 |
Exhibit 99.1 Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis —FDA Reaffirms Application is Under Priority Review with a PDUFA Target Action Date of August 12, 2025— BRIDGEWATER, N.J., February 24, 2025 /PRNewswire/ - Insmed Incorporated (Nasdaq: INSM), a people-first global biopharm |
|
| February 20, 2025 |
FIRST AMENDMENT TO REVENUE INTEREST PURCHASE AGREEMENT Exhibit 10.25.1 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10.25.1 because it (i) is not material and (ii) is the type of information the Company both customarily and actually treats as private or confidential. FIRST AMENDMENT TO REVENUE INTEREST PURCHASE AGREEMENT This FIRST AMENDMENT TO REVENUE INTEREST PURCHASE |
|
| February 20, 2025 |
Exhibit 99.1 Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $104.4 Million for Fourth-Quarter and $363.7 Million for Full-Year 2024, Reflecting 19% Annual Growth and Exceeding the Upper End of Full-Year 2024 Guidance Range— —Company Reiterates 2025 Global ARIKAYCE Revenue Guidance |
|
| February 20, 2025 |
COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENT Exhibit 10.27 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10.27 because it (i) is not material and (ii) is the type of information the Company both customarily and actually treats as private or confidential. COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENT THIS COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENT (the “Agreem |
|
| February 20, 2025 |
AMENDMENT NO. 2 TO COMMERCIALIZATION AGREEMENT BETWEEN INSMED INCORPORATED AND PARI PHARMA GMBH Exhibit 10.19.2 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10.19.2 because it (i) is not material and (ii) is the type of information the Company both customarily and actually treats as private or confidential. AMENDMENT NO. 2 TO COMMERCIALIZATION AGREEMENT BETWEEN INSMED INCORPORATED AND PARI PHARMA GMBH This seco |
|
| February 20, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) (1) Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (2) Equity Common Stock, par value $0. |
|
| February 20, 2025 |
Exhibit 10.26 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10.26 because it (i) is not material and (ii) is the type of information the Company both customarily and actually treats as private or confidential. AMENDED AND RESTATED LOAN AGREEMENT Dated as of October 31, 2024 among INSMED INCORPORATED (as Borrower, and |
|
| February 20, 2025 |
Insmed Incorporated Insider Trading Policy Effective June 10, 2024 Exhibit 19.1 Insmed Incorporated Insider Trading Policy Effective June 10, 2024 I.Introduction and Purpose This Insider Trading Policy (this “Policy”) prohibits any trading of securities while in possession of material nonpublic information gained in the course of performing services for Insmed Incorporated (the “Company”) and any unauthorized disclosure of such information. The Company is subject |
|
| February 20, 2025 |
Exhibit 10.24 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10.24 because it (i) is not material and (ii) is the type of information the Company both customarily and actually treats as private or confidential. Master Commercial Manufacturing Services Agreement PARTIES PATHEON INC. a company existing under the laws of |
|
| February 20, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission F |
|
| February 20, 2025 |
EXHIBIT 21.1 List of Subsidiaries January 2025 Name Jurisdiction of Incorporation Celtrix Pharmaceuticals, Inc. Delaware Insmed Gene Therapy LLC Delaware Insmed Limited England and Wales Insmed Holdings Limited Ireland Insmed Innovation UK Limited England and Wales Insmed Ireland Limited Ireland Insmed Netherlands Holdings B.V. The Netherlands Insmed Netherlands B.V. The Netherlands Insmed Germany |
|
| February 20, 2025 |
PRODUCT AGREEMENT Product Agreement for Brensocatib Film Coated Tablets (10mg and 25mg) and Bottling Exhibit 10.24.1 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10.24.1 because it (i) is not material and (ii) is the type of information the Company both customarily and actually treats as private or confidential. PRODUCT AGREEMENT Product Agreement for Brensocatib Film Coated Tablets (10mg and 25mg) and Bottling This |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-30739 INSMED INCORPORAT |
|
| February 20, 2025 |
Exhibit 99.2 February 2025 Investor Presentation Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein su |
|
| February 20, 2025 |
INSMED INCORPORATED 2025 INDUCEMENT PLAN Exhibit 4.1 INSMED INCORPORATED 2025 INDUCEMENT PLAN 1. Purpose The purpose of the Plan is to provide equity compensation to certain eligible individuals in order to induce such individuals to enter into employment with the Company or its Subsidiaries. The Plan is intended to meet the requirements of a plan providing for inducement grants under Rule 5635(c)(4) of the Nasdaq Listing Rules and shall |
|
| February 20, 2025 |
As filed with the Securities and Exchange Commission on February 20, 2025 As filed with the Securities and Exchange Commission on February 20, 2025 Registration No. |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 6, 2025 |
Exhibit 99.1 FDA Grants Priority Review to Insmed’s Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025 —Brensocatib Would be the First and Only Available Treatment for Bronchiectasis and First DPP1 Inhibitor, if Approved— BRIDGEWATER, N.J., February 6, 2025 /PRNewswire/ - Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical comp |
|
| January 10, 2025 |
Exhibit 99.2 January 13, 2025 JPMorgan Healthcare Conference Presentation Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncer |
|
| January 10, 2025 |
Exhibit 99.1 Insmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference —ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million— —2025 Global ARIKAYCE Revenues Expected to be Between $405 Million and $425 Million, Reflecting Continued Double-Digit Growth Comp |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission F |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED |
|
| October 31, 2024 |
Exhibit 99.1 Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter of 2023— —NDA Submission for Brensocatib in Bronchiectasis Remains on Track for the Fourth Quarter of 2024 with Potential U.S. Launch Still Expect |
|
| September 3, 2024 |
INSM / Insmed Incorporated / Darwin Global Management, Ltd. Passive Investment SC 13G 1 p24-2682sc13g.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Insmed Incorporated (Name of Issuer) Common stock, par value $0.01 per share (Title of Class of Securities) 457669307 (CUSIP Number) August 23, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designat |
|
| September 3, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99 2 p24-2682exhibit1.htm EXHIBIT 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreem |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File |
|
| August 8, 2024 |
OMNIBUS AMENDMENT TO INSMED INCORPORATED INCENTIVE AWARDS AND INDUCEMENT AWARDS May 8, 2024 Exhibit 10.2 OMNIBUS AMENDMENT TO INSMED INCORPORATED INCENTIVE AWARDS AND INDUCEMENT AWARDS May 8, 2024 WHEREAS, Insmed Incorporated (the “Company”) sponsors and maintains the Insmed Incorporated 2013 Incentive Plan, the Insmed Incorporated 2015 Incentive Plan, the Insmed Incorporated 2017 Incentive Plan and the Insmed Incorporated Amended and Restated 2019 Incentive Plan (each, a “Plan” and toge |
|
| August 8, 2024 |
Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10. |
|
| August 8, 2024 |
AMENDMENT NO. 1 TO COMMERCIALIZATION AGREEMENT BETWEEN INSMED INCORPORATED AND PARI PHARMA GMBH Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10. |
|
| August 8, 2024 |
Exhibit 10.1.4 INSMED INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR NON-U.S. GRANTEES Grantee Name: /$ParticipantName$/ Number of RSUs: /$AwardsGranted$/ Grant Date: /$GrantDate$/ Pursuant to the Insmed Incorporated Amended and Restated 2019 Incentive Plan (the “Plan”) as amended through the date hereof and this Restricted Stock Unit Awar |
|
| August 8, 2024 |
INSMED INCORPORATED NONQUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT FOR NON-US EMPLOYEES Exhibit 10.4 INSMED INCORPORATED NONQUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT FOR NON-US EMPLOYEES No. of shares subject to Option: /$AwardsGranted$/ THIS AGREEMENT dated this /$GrantDate$/ (this “Agreement”), between INSMED INCORPORATED, a Virginia corporation (the “Company”), and [NAME] (the “Participant”), is an inducement material to Participant’s entry into employment with the Company |
|
| August 8, 2024 |
Exhibit 99.1 Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $90.3 Million for the Second Quarter of 2024, Reflecting 17% Growth Over the Second Quarter of 2023— —U.S. Launch Readiness for Brensocatib in Bronchiectasis Remains on Track with NDA Submission Expected in the Fourth Quarter of 2024— |
|
| August 8, 2024 |
Exhibit 10.1.3 INSMED INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR U.S. GRANTEES Grantee Name: /$ParticipantName$/ Number of RSUs: /$AwardsGranted$/ Grant Date: /$GrantDate$/ Pursuant to the Insmed Incorporated Amended and Restated 2019 Incentive Plan (the “Plan”) as amended through the date hereof and this Restricted Stock Unit Award Ag |
|
| August 8, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INCO |
|
| August 8, 2024 |
Exhibit 10.1.2 INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR NON-U.S. PARTICIPANTS No. of shares subject to Option: /$AwardsGranted$/ THIS NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) dated this /$GrantDate$/, between INSMED INCORPORATED, a Virginia corporation (the "Company"), and /$ParticipantName$/ ("Participant"), is |
|
| August 8, 2024 |
Exhibit 10.1.1 INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR U.S. PARTICIPANTS No. of shares subject to Option: /$AwardsGranted$/ THIS NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) dated this /$GrantDate$/, between INSMED INCORPORATED, a Virginia corporation (the "Company"), and /$ParticipantName$/ ("Participant"), is made |
|
| August 8, 2024 |
INSMED INCORPORATED NONQUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT Exhibit 10.3 INSMED INCORPORATED NONQUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT No. of shares subject to Option: /$AwardsGranted$/ THIS AGREEMENT dated this /$GrantDate$/ (this “Agreement”), between INSMED INCORPORATED, a Virginia corporation (the “Company”), and /$ParticipantName$/ (the “Participant”), is an inducement material to Participant’s entry into employment with the Company or a su |
|
| July 3, 2024 |
Exhibit 99.1 Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference —New Graph Depicting 52-Week FEV1 Data Illustrate Significantly Less Decline in Lung Function for Brensocatib 25 mg Versus Placebo— —Additional Exploratory Endpoints to be Presented, Including FVC and Patient-Reported BEST Score— B |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File N |
|
| July 3, 2024 |
Exhibit 99.2 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Patients With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study James D. Chalmers,1 Pierre-Régis Burgel,2 Charles L. Daley,3 Anthony De Soyza,4 Charles S. Haworth,5 David Mauger,6 Kevin Mange,7 Ariel Teper,7 Carlos Fer |
|
| June 27, 2024 |
Exhibit 99.1 Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025 BRIDGEWATER, N.J., June 27, 2024/PRNewswire/ - Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it has called all $225 million aggregate principal amount of its |
|
| June 27, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 4, 2024 |
Insmed Incorporated Commercial Presentation June 4, 2024 Exhibit 99.1 Insmed Incorporated Commercial Presentation June 4, 2024 Forward Looking Statement Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a num |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| May 30, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Number 333-272088 PROSPECTUS SUPPLEMENT (To Prospectus dated May 19, 2023) 12,621,359 Shares Common Stock We are offering 12,621,359 shares of our common stock. |
|
| May 30, 2024 |
INSMED INCORPORATED Common Stock, Par Value $0.01 Per Share Underwriting Agreement Exhibit 1.1 EXECUTION VERSION INSMED INCORPORATED Common Stock, Par Value $0.01 Per Share Underwriting Agreement May 29, 2024 Goldman Sachs & Co. LLC Leerink Partners LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC 200 West Street, New York, New York 10282 c/o Leerink Partners LLC 53 State Street, 40th Floor Boston, |
|
| May 30, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE 424(b)(5) (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Fees to be Paid Equity Common Stock, par value $0. |
|
| May 30, 2024 |
Insmed Announces Proposed $500 Million Public Offering of Common Stock Exhibit 99.1 Insmed Announces Proposed $500 Million Public Offering of Common Stock BRIDGEWATER, N.J., May 28, 2024 /PRNewswire/ - Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it intends to offer and sell $500 million of shares of its common stock in an underwritten public |
|
| May 30, 2024 |
Insmed Announces Pricing of $650 Million Public Offering of Common Stock Exhibit 99.2 Insmed Announces Pricing of $650 Million Public Offering of Common Stock BRIDGEWATER, N.J., May 30, 2024 /PRNewswire/ - Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it priced an underwritten public offering of 12,621,359 shares of its common stock at a price t |
|
| May 29, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Number 333-272088 The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 28, 2024 |
Exhibit 99.2 ASPEN Topline Results May 28, 2024 Forward Looking Statement Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncer |
|
| May 28, 2024 |
Exhibit 99.1 Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis —Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo— —Treatment with Brensocatib Also Achieves Statistical Significance |
|
| May 14, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| May 14, 2024 |
As filed with the Securities and Exchange Commission on May 14, 2024 As filed with the Securities and Exchange Commission on May 14, 2024 Registration No. |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 9, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INC |
|
| May 9, 2024 |
Exhibit 99.1 Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update — ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $75.5 Million for the First Quarter of 2024, Reflecting 16% Annual Growth Over the First Quarter of 2023— —Company Reports Positive Topline Safety and Tolerability Data from the Phase 2 PH-ILD Study of TPIP with 79.3% of Patients Reach |
|
| May 9, 2024 |
Exhibit 99.2 May 2024 TPIP Phase 2 PH-ILD Topline Results & Phase 2 PAH Blended Blinded Data Update Forward Looking Statement Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not hist |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 1, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File |
|
| February 22, 2024 |
INSMED INCORPORATED Shares of Common Stock ($0.01 par value per share) SALES AGREEMENT Exhibit 10.1 Execution Version INSMED INCORPORATED Shares of Common Stock ($0.01 par value per share) SALES AGREEMENT February 22, 2024 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Insmed Incorporated, a Virginia corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: |
|
| February 22, 2024 |
AMENDED AND RESTATED RECOUPMENT POLICY Exhibit 97 AMENDED AND RESTATED RECOUPMENT POLICY I.Purpose. Insmed Incorporated (the “Company”) is establishing this amended and restated recoupment policy (this “Policy”) to appropriately align the interests of the Executive Officers with those of the Company. This Policy has been approved by the Board and is effective as of [October 2], 2023 (the “Effective Date”). This Policy is intended to co |
|
| February 22, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-272088 PROSPECTUS SUPPLEMENT (To Prospectus dated May 19, 2023) $500,000,000 Common Stock We have entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”) dated February 22, 2024, relating to shares of our common stock, par value $0.01 per share, offered by this prospectus supplem |
|
| February 22, 2024 |
Entry into a Material Definitive Agreement, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission F |
|
| February 22, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-30739 |
|
| February 22, 2024 |
Exhibit 99.1 Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update —Topline Data from the Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis Remain on Track to Read Out in the Latter Part of Second-Quarter 2024— —Enrollment in the Phase 2 Study of TPIP in Patients with PH-ILD Completed in November 2023; Topline Data Expected in Second |
|
| February 22, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) INSMED INCORPORATED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee(2) Newly Registered Securities Fees to Be Paid Equity Common Stock, $0. |
|
| February 22, 2024 |
EXHIBIT 21.1 List of Subsidiaries January 2024 Name Jurisdiction of Incorporation Adrestia Therapeutics Inc. Delaware Celtrix Pharmaceuticals, Inc. Delaware Insmed Gene Therapy LLC Delaware Insmed Limited England and Wales Insmed Holdings Limited Ireland Insmed Innovation UK Limited England and Wales Insmed Ireland Limited Ireland Insmed Netherlands Holdings B.V. The Netherlands Insmed Netherlands |
|
| February 13, 2024 |
INSM / Insmed Incorporated / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01192-insmedinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Insmed Inc Title of Class of Securities: Common Stock CUSIP Number: 457669307 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule purs |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 5, 2024 |
Exhibit 99.2 J.P. Morgan Healthcare Conference January 2024 Forward Looking Statement Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of ris |
|
| January 5, 2024 |
Exhibit 99.1 Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference —ARIKAYCE® (amikacin liposome inhalation suspension) Delivers Full-Year 2023 Revenues Exceeding the Upper End of Guidance Range with Unaudited Global Net Product Sales of Approximately $305.2 Million— —2024 Global ARIKAYCE Revenues Expected to be Between $340 Million and $360 Million, Reflecting Double-Di |
|
| November 13, 2023 |
INSM / Insmed Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Insmed Inc Title of Class of Securities: Common Stock CUSIP Number: 457669307 Date of Event Which Requires Filing of this Statement: October 31, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d- |
|
| October 26, 2023 |
Exhibit 99.1 Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $79.1 Million for the Third Quarter of 2023 Reflects Highest Quarter of Sales Since Launch and 17% Growth Compared to the Third Quarter of 2022— —Company Reiterates Full-Year 2023 Guidance Range for Global ARIKAYCE Revenues of $295 Mill |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED |
|
| October 26, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fi |
|
| September 5, 2023 |
Exhibit 99.2 ARISE Topline Results September 5, 2023 Forward Looking Statement Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and |
|
| September 5, 2023 |
Exhibit 99.1 INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ARISE STUDY OF ARIKAYCE® (AMIKACIN LIPOSOME INHALATION SUSPENSION) IN PATIENTS WITH NTM LUNG DISEASE CAUSED BY MAC —QOL-B Respiratory Domain Shown to Work Effectively as Patient-Reported Outcome Tool in Patients with MAC Lung Disease; to be Proposed to FDA as Primary Endpoint in ENCORE with No Modifications— —Patients Treated with |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission F |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INCO |
|
| August 3, 2023 |
Exhibit 99.1 Insmed Reports Second-Quarter 2023 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $77.2 Million for the Second Quarter of 2023 Reflects Highest Quarter of Sales Since Launch and 18% Growth Compared to the Second Quarter of 2022— —Company Raises Full-Year 2023 Guidance Range for Global ARIKAYCE Revenues to $295 Milli |
|
| August 3, 2023 |
INSMED INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR U. |
|
| August 3, 2023 |
INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR NON-U. |
|
| August 3, 2023 |
INSMED INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR NON-U. |
|
| August 3, 2023 |
INSMED INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR MEMBERS OF THE BOARD OF DIRECTORS Grantee Name: [NAME] Number of RSUs: [AMOUNT] Grant Date: [DATE] Pursuant to the Insmed Incorporated Amended and Restated 2019 Incentive Plan (the “Plan”) as amended through the date hereof and this Restricted Stock Unit Award Agreement (this “Agreement”), Insmed Incorporated (the “Company”) hereby grants an award of [AMOUNT] restricted stock units (the “Restricted Stock Units” or the “RSU Award”) to the individual named above (the “Grantee”). |
|
| August 3, 2023 |
INSMED INCORPORATED PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE 2019 INCENTIVE PLAN FOR U. |
|
| August 3, 2023 |
INSMED INCORPORATED PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE 2019 INCENTIVE PLAN FOR NON-U. |
|
| August 3, 2023 |
INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR U. |
|
| August 3, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File |
|
| May 19, 2023 |
As filed with the Securities and Exchange Commission on May 19, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 19, 2023 Registration No. |
|
| May 19, 2023 |
Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) [] COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of trustee as specified in its charter) |
|
| May 19, 2023 |
As filed with the Securities and Exchange Commission on May 19, 2023 As filed with the Securities and Exchange Commission on May 19, 2023 Registration No. |
|
| May 19, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| May 19, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) INSMED INCORPORATED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Primary Fees to Be Paid Equity Common Stock, $0. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 11, 2023 |
AMENDED AND RESTATED BYLAWS INSMED INCORPORATED ARTICLE I MEETINGS OF SHAREHOLDERS Exhibit 3.1 AMENDED AND RESTATED BYLAWS of INSMED INCORPORATED ARTICLE I MEETINGS OF SHAREHOLDERS SECTION 1. Place of Meetings. All meetings of the shareholders of Insmed Incorporated (hereinafter called the “Corporation”) shall be held (i) at such place, either within or outside of the Commonwealth of Virginia, as may from time to time be fixed by the Board of Directors of the Corporation (herein |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 8, 2023 |
Exhibit 99.1 Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, “The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More” —Early-Stage Research Pillar Anticipated to Generate at Least Six Investigational New Drug (IND) Applications by End of 2025— —Company Reveals Select Initial Disease Targets for Next-Generation Gene Therap |
|
| May 8, 2023 |
Exhibit 99.2 The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More 6 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INC |
|
| May 4, 2023 |
Exhibit 99.1 Insmed Reports First Quarter 2023 Financial Results and Provides Business Update —Enrollment Complete in Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis; Topline Data Readout on Track for Second Quarter of 2024— —Company to Provide Detailed Update on Early-Stage Research Programs on May 8, 2023— —Company on Track to Share Topline Data from Post-Marketing ARISE |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 4, 2023 |
INSMED INCORPORATED NONQUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT INSMED INCORPORATED NONQUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT No. of shares subject to Option: /$AwardsGranted$/ THIS AGREEMENT dated this /$GrantDate$/ (this “Agreement”), between INSMED INCORPORATED, a Virginia corporation (the “Company”), and /$ParticipantName$/ (the “Participant”), is an inducement material to Participant’s entry into employment with the Company or a subsidiary of t |
|
| May 4, 2023 |
INSMED INCORPORATED NONQUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT INSMED INCORPORATED NONQUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT No. of shares subject to Option: /$AwardsGranted$/ THIS AGREEMENT dated this /$GrantDate$/ (this “Agreement”), between INSMED INCORPORATED, a Virginia corporation (the “Company”), and /$ParticipantName$/ (the “Participant”), is an inducement material to Participant’s entry into employment with the Company or a subsidiary of t |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| February 23, 2023 |
Exhibit 99.2 Fourth Quarter and Full Year 2022 Financial Results February 23, 2023 This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words he |
|
| February 23, 2023 |
Exhibit 99.1 Insmed Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update —Patient Screening Complete in Adult Patients in Phase 3 ASPEN Trial of Brensocatib in Bronchiectasis; Topline Data Readout on Track for Second Quarter of 2024— —Company to Share Robust Updates Across Early-Stage Programs at Research Day on May 8, 2023— —Company on Track to Share Topline Da |
|
| February 23, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-30739 |
|
| February 23, 2023 |
EXHIBIT 21.1 List of Subsidiaries January 2023 Name Jurisdiction of Incorporation Celtrix Pharmaceuticals, Inc. Delaware Insmed Gene Therapy LLC Delaware Insmed Limited England and Wales Insmed Holdings Limited Ireland Insmed Ireland Limited Ireland Insmed Netherlands Holdings B.V. The Netherlands Insmed Netherlands B.V. The Netherlands Insmed Germany GmbH Germany Insmed France SAS France Insmed G |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission F |
|
| February 9, 2023 |
INSM / Insmed Incorporated / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Insmed Inc. Title of Class of Securities: Common Stock CUSIP Number: 457669307 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13 |
|
| January 6, 2023 |
Exhibit 99.2 Investor Presentation January 2023 Forward Looking Statement Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. ?Forward-looking statements,? as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncer |
|
| January 6, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 6, 2023 |
Exhibit 99.1 Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference ?Topline Data from Phase 2 PK/PD Study of Brensocatib in Patients with Cystic Fibrosis Show Clear Dose Response at all Evaluated Doses? ?Treatment Discontinuation Rate of 15% Reported in Postmarketing ARISE Trial of ARIKAYCE? (amikacin liposome inhalation suspension) in Fr |
|
| October 27, 2022 |
EXHIBIT 10.3 August 8, 2022 Roger Adsett Chief Operating Officer 5 Swallow Hill Road Greenville, DE 19807 RE: Employment Agreement Dear Roger, Insmed Incorporated (“Insmed”) and you are parties to the Amended and Restated Employment Agreement, dated April 1, 2022 (the “Agreement”). All capitalized terms not otherwise defined in this letter agreement shall have the meanings ascribed to such terms i |
|
| October 27, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 27, 2022 |
Ex. 10.2 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10.2 because it (i) is not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. LOAN AGREEMENT Dated as of October 19, 2022 among INSMED INCORPORATED (as Borrower, and a Credit Party), THE GUARANTORS SIGNATORY HERETO OR OT |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED |
|
| October 27, 2022 |
Exhibit 99.1 Insmed Reports Third Quarter 2022 Financial Results and Provides Business Update ?ARIKAYCE? (amikacin liposome inhalation suspension) Achieves 45% Year Over Year Growth for the Third Quarter of 2022 with Total Revenue of $67.7 Million, Marking the Strongest Quarter Since Launch? ?Clinical Programs Progressing on Track; Company Expects to Complete Enrollment in Phase 3 ASPEN Trial of B |
|
| October 27, 2022 |
Ex. 10.1 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10.1 because it (i) is not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. REVENUE INTEREST PURCHASE AGREEMENT DATED AS OF OCTOBER 19, 2022 BETWEEN INSMED INCORPORATED, AND ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, L |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2022 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction (Commission (IRS Employer of inc |
|
| October 20, 2022 |
EX-99.1 4 ny20005570x4ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Insmed Announces Strategic Financings Totaling $775 Million —$500 million secured in non-dilutive structured financings consisting of a term loan and capped royalty financing— —$275 million underwritten offering of common stock— —Financings increase cash and cash equivalents and marketable securities to approximately $1.3 billion— BRIDGEWA |
|
| October 20, 2022 |
13,750,000 Shares INSMED INCORPORATED Common Stock, Par Value $0.01 Per Share UNDERWRITING AGREEMENT Exhibit 1.1 13,750,000 Shares INSMED INCORPORATED Common Stock, Par Value $0.01 Per Share UNDERWRITING AGREEMENT October 19, 2022 J.P. Morgan Securities LLC SVB Securities LLC as Representatives of the several Underwriters c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o SVB Securities LLC 53 State Street, 40th Floor Boston, MA 02109 Ladies and Gentlemen: Insmed Incorporate |
|
| October 19, 2022 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common stock, par value $0. |
|
| October 19, 2022 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Number 333-238560 PROSPECTUS SUPPLEMENT (To Prospectus dated May 21, 2020) 13,750,000 Shares ? Common Stock We are offering 13,750,000 shares of our common stock. |
|
| October 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2022 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction (Commission (IRS Employer of inc |
|
| August 4, 2022 |
EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is effective on May 23, 2022 (the ?Effective Date?), by and between Insmed Incorporated, a Virginia corporation (?Insmed?), and J. |
|
| August 4, 2022 |
Exhibit 99.1 Insmed Reports Second Quarter 2022 Financial Results and Provides Business Update ?ARIKAYCE? (amikacin liposome inhalation suspension) Achieves 44% Year Over Year Growth for the Second Quarter of 2022 with Total Revenue of $65.2 Million, Marking the Strongest Quarter Since Launch? ?All Clinical Programs Progressing on Track? ?Company Reiterates Guidance of at Least 30% Revenue Growth |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INCO |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| May 23, 2022 |
Insmed Names Drayton Wise Chief Commercial Officer Exhibit 99.1 Insmed Names Drayton Wise Chief Commercial Officer BRIDGEWATER, N.J., May 23, 2022 /PRNewswire/ ? Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Drayton Wise as Chief Commercial Officer, effective May 23, 2022. In addition to his current responsibil |
|
| May 19, 2022 |
As filed with the Securities and Exchange Commission on May 19, 2022 As filed with the Securities and Exchange Commission on May 19, 2022 Registration No. |
|
| May 19, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| May 5, 2022 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (?Agreement?) is effective on April 1, 2022 (the ?Effective Date?), by and between Insmed Incorporated, a Virginia corporation (?Insmed?), and Michael Smith (hereinafter, the ?Executive? and collectively with Insmed, the ?Parties?). |
|
| May 5, 2022 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (?Agreement?) is effective on April 1, 2022 (the ?Effective Date?), by and between Insmed Incorporated, a Virginia corporation (?Insmed?), and S. |
|
| May 5, 2022 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (?Agreement?) is effective on April 1, 2022 (the ?Effective Date?), by and between Insmed Incorporated, a Virginia corporation (?Insmed?), and Sara Bonstein (hereinafter, the ?Executive? and collectively with Insmed, the ?Parties?). |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INC |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 5, 2022 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (?Agreement?) is effective on April 1, 2022 (the ?Effective Date?), by and between Insmed Incorporated, a Virginia corporation (?Insmed?), and Roger Adsett (hereinafter, the ?Executive? and collectively with Insmed, the ?Parties?). |
|
| May 5, 2022 |
Exhibit 99.1 Insmed Reports First Quarter 2022 Financial Results and Provides Business Update ?ARIKAYCE? (amikacin liposome inhalation suspension) Achieves 32% Year Over Year Growth for the First Quarter of 2022 with Total Revenue of $53.1 Million? ?Seven Clinical Trials Underway; Enrollment on Track in Brensocatib Phase 3 ASPEN Study and ARIKAYCE Post-Marketing Studies (ARISE and ENCORE)? ?Compan |
|
| May 5, 2022 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (?Agreement?) is effective on April 1, 2022 (the ?Effective Date?), by and between Insmed Incorporated, a Virginia corporation (?Insmed?), and Martina Flammer (hereinafter, the ?Executive? and collectively with Insmed, the ?Parties?). |
|
| April 1, 2022 |
DEF 14A 1 ny20001684x1def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| February 17, 2022 |
INSMED INCORPORATED PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE 2019 INCENTIVE PLAN FOR NON-U. |
|
| February 17, 2022 |
EX-10.4.2 2 insm20211231ex1042.htm EX-10.4.2 INSMED INCORPORATED AMENDMENT TO RESTRICTED UNIT AWARD AGREEMENT UNDER THE 2017 INCENTIVE PLAN FOR U.S. EMPLOYEES This Amendment to Restricted Unit Award Agreement under the 2017 Incentive Plan for U.S. Employees (this “Amendment”) is entered into as of [●], 2021 (the “Effective Date”) by and between Insmed Incorporated (the “Company”) and [●] (the “Gra |
|
| February 17, 2022 |
Exhibit 99.2 February 17, 2022 This presentation contains forward-looking statements that involve substantial risks and uncertainties. ?Forward-looking statements,? as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as ?may,? ?will,? ?should,? ?could,? ?woul |
|
| February 17, 2022 |
INSMED INCORPORATED PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE 2019 INCENTIVE PLAN FOR U. |
|
| February 17, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-30739 |
|
| February 17, 2022 |
INSMED INCORPORATED RESTRICTED UNIT AWARD AGREEMENT UNDER THE 2019 INCENTIVE PLAN FOR NON-U. |
|
| February 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):February 15, 2022 INSMED INCORPORATED Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction (Commission (IRS Employer of inco |
|
| February 17, 2022 |
Exhibit 99.1 Insmed Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business and Pipeline Update ?ARIKAYCE? (amikacin liposome inhalation suspension) Total Revenue of $56.1 Million for the Fourth Quarter and $188.5 Million for the Full Year 2021; Anticipate at Least 30% Year Over Year Annual Growth for 2022? ?Enrollment Timelines Provided for Brensocatib Phase 3 ASPEN Stud |
|
| February 17, 2022 |
EXHIBIT 21.1 List of Subsidiaries January 2022 Name Jurisdiction of Incorporation Celtrix Pharmaceuticals, Inc. Delaware Insmed Limited England and Wales Insmed Holdings Limited Ireland Insmed Ireland Limited Ireland Insmed Netherlands B.V. The Netherlands Insmed Germany GmbH Germany Insmed France SAS France Insmed Godo Kaisha Japan Insmed Switzerland GmbH Switzerland Insmed Italy S.R.L. Italy |
|
| February 10, 2022 |
INSM / Insmed Incorporated / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Insmed Inc. Title of Class of Securities: Common Stock CUSIP Number: 457669307 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13 |
|
| January 10, 2022 |
Exhibit 99.1 This presentation contains forward-looking statements that involve substantial risks and uncertainties. ?Forward-looking statements,? as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as ?may,? ?will,? ?should,? ?could,? ?would,? ?expects,? ?pl |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED |
|
| October 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 28, 2021 |
EX-10.3 4 insm20210930ex103.htm EX-10.3 INSMED INCORPORATED AMENDMENT TO RESTRICTED UNIT AWARD AGREEMENT UNDER THE 2019 INCENTIVE PLAN FOR U.S. EMPLOYEES This Amendment to Restricted Unit Award Agreement under the 2019 Incentive Plan for U.S. Employees (this “Amendment”) is entered into as of [●], 2021 (the “Effective Date”) by and between Insmed Incorporated (the “Company”) and [●] (the “Grantee” |
|
| October 28, 2021 |
EX-10.5 6 insm20210930ex105.htm EX-10.5 INSMED INCORPORATED PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE 2019 INCENTIVE PLAN FOR NON-U.S. GRANTEES Grantee Name: /$ParticipantName$/ Target Number of PSUs: /$AwardsGranted$/ Grant Date: /$GrantDate$/ Pursuant to the Insmed Incorporated 2019 Incentive Plan (the “Plan”) as amended through the date hereof and this Performance-Based |
|
| October 28, 2021 |
EX-99.1 2 brhc10030173ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Insmed Reports Third Quarter 2021 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Now Launched in Three Major Territories; Positive Early Trends in Japan— —Continuing to Advance ARIKAYCE, Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) Clinical Development Programs— —ARIKA |
|
| October 28, 2021 |
INSMED INCORPORATED PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE 2019 INCENTIVE PLAN FOR U. |
|
| October 28, 2021 |
INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE 2019 INCENTIVE PLAN INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE 2019 INCENTIVE PLAN No. |
|
| October 28, 2021 |
INSMED INCORPORATED RESTRICTED UNIT AWARD AGREEMENT UNDER THE 2019 INCENTIVE PLAN FOR U.S. EMPLOYEES INSMED INCORPORATED RESTRICTED UNIT AWARD AGREEMENT UNDER THE 2019 INCENTIVE PLAN FOR U. |
|
| August 5, 2021 |
SECOND AMENDMENT TO EMPLOYMENT AGREEMENT EX-10.3 4 insm20210630ex103.htm EX-10.3 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to EMPLOYMENT AGREEMENT (this “Second Amendment”), is made and entered into as of July 23, 2021 (the “Effective Date”) by and between Insmed Incorporated, a Virginia corporation (the “Company”), and Roger Adsett (the “Executive”) (each of the Executive and the Company, a “Party”, and collectively |
|
| August 5, 2021 |
Exhibit 99.1 Insmed Reports Second Quarter 2021 Financial Results and Provides Business Update ?ARIKAYCE? (amikacin liposome inhalation suspension) Now Launched in Japan; Available in Three Major Territories? ?Continuing to Progress ARIKAYCE, Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) Clinical Development Programs? ?ARIKAYCE Total Revenue of $45.4 Million for the Second Quarte |
|
| August 5, 2021 |
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT EX-10.4 5 insm20210630ex104.htm EX-10.4 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to EMPLOYMENT AGREEMENT (this “First Amendment”), is made and entered into as of July 23, 2021 (the “Effective Date”) by and between Insmed Incorporated, a Virginia corporation (the “Company”), and Martina Flammer (the “Executive”) (each of the Executive and the Company, a “Party”, and collectively |
|
| August 5, 2021 |
EX-10.1 2 insm20210630ex101.htm EX-10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is effective on July 8, 2021 (the “Effective Date”), by and between Insmed Incorporated, a Virginia corporation (“Insmed”), and Michael Smith (hereinafter, the “Executive”). When referring to the Executive, the term “he” or “she” throughout this Agreement is intended to be gender neutral. WITNESSET |
|
| August 5, 2021 |
June 21, 2021 Christine Pellizzari 14459 Marsala Way Naples, FL 34109 Dear Christine: This letter, upon signature by the parties, will constitute our agreement (?Agreement?) effective July 8, 2021 (the ?Effective Date?) concerning the services of Christine Pellizzari (?Consultant?) as a consultant to Insmed Incorporated (?Company?). |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INCO |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File |
|
| June 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File |
|
| May 19, 2021 |
As filed with the Securities and Exchange Commission on May 19, 2021 As filed with the Securities and Exchange Commission on May 19, 2021 Registration No. |
|
| May 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 13, 2021 |
EX-99.1 7 nt10024340x6ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Insmed Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028 BRIDGEWATER, NJ, May 10, 2021 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM) announced today that it intends to offer and sell $250 million of its common stock (the “Shares”) and $500 million aggregate principal amount of its conv |
|
| May 13, 2021 |
EX-99.1 3 nt10024340x7ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Insmed Announces Closing of Public Offerings of Common Stock and Convertible Senior Notes and Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes BRIDGEWATER, NJ, May 13, 2021 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM) announced today the closing of the previously announced registered underwritten public o |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2021 INSMED INCORPORATED (Exact Name of Registrant as Specified in Charter) Virginia 000-30739 54-1972729 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| May 13, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2021 INSMED INCORPORATED (Exact Name of Registrant as Specified in Charter) Virginia (State or Other Jurisdiction of Incorporation) 000-30739 (Commission File Number) 54-1972729 (I. |
|
| May 13, 2021 |
10,000,000 Shares INSMED INCORPORATED Common Stock, Par Value $0.01 Per Share UNDERWRITING AGREEMENT EX-1.1 2 nt10024340x6ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 10,000,000 Shares INSMED INCORPORATED Common Stock, Par Value $0.01 Per Share UNDERWRITING AGREEMENT May 10, 2021 J.P. Morgan Securities LLC SVB Leerink LLC as Representatives of the several Underwriters c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, MA 02110 Ladi |
|
| May 13, 2021 |
EX-4.2 2 nt10024340x7ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 INSMED INCORPORATED AND WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee Second Supplemental Indenture Dated as of May 13, 2021 to Indenture Dated as of January 26, 2018 0.75% Convertible Senior Notes due 2028 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 2 Section 1.01 Definitions 2 Section 1.02 References to Interest 10 ARTICLE 2 ISSUE, DES |
|
| May 13, 2021 |
INSMED INCORPORATED 0.75% Convertible Senior Notes due 2028 UNDERWRITING AGREEMENT EX-1.2 3 nt10024340x6ex1-2.htm EXHIBIT 1.2 Exhibit 1.2 INSMED INCORPORATED 0.75% Convertible Senior Notes due 2028 UNDERWRITING AGREEMENT May 10, 2021 J.P. Morgan Securities LLC SVB Leerink LLC As Managers of the several Underwriters listed in Schedule I hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, MA 02110 L |
|
| May 13, 2021 |
Exhibit 5.3 May 13, 2021 Insmed Incorporated 700 US Highway 202/206 Bridgewater, NJ 08807 Ladies and Gentlemen: We have acted as special counsel to Insmed Incorporated, a Virginia corporation (the ?Company?), in connection with the registration by the Company under the Securities Act of 1933, as amended (the ?Securities Act?) of (i) $575,000,000 aggregate principal amount of its 0.75% Convertible |
|
| May 13, 2021 |
EX-99.2 8 nt10024340x6ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Insmed Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028 BRIDGEWATER, NJ, May 11, 2021 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM) announced today that it priced a registered underwritten public offering of 10,000,000 shares of its common stock (the “Shares”) at a price to the publ |
|
| May 12, 2021 |
CALCULATION OF REGISTRATION FEE 424B5 1 nt10024340x5424b5.htm 424B5 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Number 333-238560 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount of Securities to be Registered(1) Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) 0.75% Convertible Senior Notes due 2028 $575,000,000 $575,000,000 $62,732.50 Common St |
|
| May 12, 2021 |
CALCULATION OF REGISTRATION FEE TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Number 333-238560 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount of Securities to be Registered(1) Proposed Maximum Offering Price per Security Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, par value $0. |
|
| May 11, 2021 |
Issuer Free Writing Prospectus dated May 10, 2021 Filed Pursuant to Rule 433 Registration No. |
|
| May 10, 2021 |
SUBJECT TO COMPLETION, DATED MAY 10, 2021 424B5 1 nt10024340x1424b5.htm 424B5 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has become effective by rule of the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are n |
|
| May 10, 2021 |
SUBJECT TO COMPLETION, DATED MAY 10, 2021 424B5 1 nt10024340x2424b5.htm 424B5 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has become effective by rule of the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are n |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INC |
|
| May 6, 2021 |
AMENDMENT TO THE TECHNOLOGY TRANSFER AGREEMENT AND TO THE MANUFACTURING AND SUPPLY AGREEMENT EX-10.3 3 insm-20210331ex103.htm EX-10.3 EX-10.3 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10.3 because it (i) is not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. AMENDMENT TO THE TECHNOLOGY TRANSFER AGREEMENT AND TO THE MANUFACTURING AND SUPPLY AGREEMENT This amen |
|
| May 6, 2021 |
Exhibit 99.1 Insmed Reports First Quarter 2021 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Approved in Japan for Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to Prior Treatment with a Multidrug Regimen— —ARIKAYCE European Launch Under Way with Commercial Sales in Germany and the Netherlands— —Enrollment Progre |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 6, 2021 |
EX-10.1 2 insm20210331ex101.htm EX-10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is effective on the Commencement Date (as defined below), by and between Insmed Incorporated, a Virginia corporation (the “Company”), and Martina Flammer (hereinafter, the “Executive”). When referring to the Executive, the term “he” or “she” throughout this Agreement is intended to be gender neutra |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2021 INSMED INCORPORATED (Exact Name of Registrant as Specified in Charter) Virginia 000-30739 54-1972729 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| February 25, 2021 |
INSMED INCORPORATED Shares of Common Stock ($0.01 par value per share) SALES AGREEMENT Exhibit 10.1 Execution Version INSMED INCORPORATED Shares of Common Stock ($0.01 par value per share) SALES AGREEMENT February 25, 2021 SVB LEERINK LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Insmed Incorporated, a Virginia corporation (the ?Company?), confirms its agreement (this ?Agreement?) with SVB Leerink LLC (the ?Agent?), as follows: 1. Issuanc |
|
| February 25, 2021 |
INSMED INCORPORATED RESTRICTED UNIT AWARD AGREEMENT UNDER THE 2019 INCENTIVE PLAN FOR U.S. EMPLOYEES INSMED INCORPORATED RESTRICTED UNIT AWARD AGREEMENT UNDER THE 2019 INCENTIVE PLAN FOR U. |
|
| February 25, 2021 |
INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE 2019 INCENTIVE PLAN EX-10.5.3 5 insm20201231ex1053.htm EX-10.5.3 INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE 2019 INCENTIVE PLAN No. of shares subject to Option: [] THIS AGREEMENT dated this [], between INSMED INCORPORATED, a Virginia corporation (the "Company"), and [] ("Participant"), is made pursuant and subject to the provisions of the Insmed Incorporated 2019 Incentive Plan, as amended (th |
|
| February 25, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-30739 |
|
| February 25, 2021 |
Description of Securities Registered Under Section 12 of the Exchange Act Exhibit 4.5 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following information is a summary of the material terms of the common stock of Insmed Incorporated (?we?, ?our? and ?us,?), which is based upon, and is qualified in its entirety by reference to, our Articles of Incorporation, as amended (the ?Articles of Incorporation?), our Amended and Re |
|
| February 25, 2021 |
Exhibit 99.1 Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update ?ARIKAYCE EU Launch Progresses, with Product Now Available and Reimbursed in Germany and the Netherlands? ?Frontline Clinical Trial Program of ARIKAYCE(R) (amikacin liposome inhalation suspension) in Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium avium complex (MAC) |
